Abstract: A cartridge for an image forming apparatus includes: a process unit to be used to form an image; a first member including a first resin material; a second member including a second resin material having higher flame retardant capability than the first resin material; and an electrode member including a contact section configured to be supplied with power from an apparatus main body of the image forming apparatus. The electrode member is configured to electrically connect the apparatus main body to the process unit. The second resin material of the second member has a greater density than the first resin material of the first member. The contact section is located in the vicinity of the first and second members and is closer to the second member than to the first member.

Abstract: An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon ? by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.

Abstract: A build apparatus builds a first structural layer by irradiating a first beam position, builds a first build object and irradiating the first build object, a second irradiation beam position builds a second build object. The build apparatus further builds a second structural layer by irradiating the first structural layer, a third irradiation beam position builds a third build object and by irradiating the third build object, a fourth irradiation beam position builds a fourth build object. At least one of a distance between first and second position and a distance between third and fourth position is shorter than a distance between second and third position. Thus, the build apparatus builds a structural object including the first and second structural objects and is inclined with respect to an optical axis direction.

Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.

Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.

Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.

Abstract: A solid-state imaging element includes a pixel and an image processing unit. The pixel has a common transistor, a charge accumulation unit, and a power supply. The common transistor has a first terminal and a second terminal. The common transistor maintains a voltage of the first terminal at a predetermined voltage with a voltage applied from the power supply and outputs a voltage corresponding to a change in a voltage of the charge accumulation unit from the second terminal, based on a condition that an element voltage is a ground voltage. The common transistor outputs a voltage corresponding to a change in a voltage of the charge accumulation unit from the first terminal, based on the element voltage is higher than the ground voltage. The image processing unit generates a luminance image according to a change in the voltage output from the second terminal of the common transistor.

Abstract: An image forming apparatus includes a stacking portion including a lifting portion, a feeding member feeding a sheet stacked on the lifting portion to a conveyance passage, a position detector detecting movement of the sheet stacked on to a feedable position to the conveyance passage, a driver including a motor and performing the lifting operation of the lifting portion, a rotation detector detecting rotation of the motor, and a controller. The controller determines a factor that the position detector does not detect the movement of the sheet stacked on the lifting portion to the feedable position within a predetermined time based on a detection result of the rotation detector while controlling the driver to lift up the lifting portion.

Abstract: A solid-state imaging element includes a pixel and an image processing unit. The pixel has a common transistor, a charge accumulation unit, and a power supply. The common transistor has a first terminal and a second terminal. The common transistor maintains a voltage of the first terminal at a predetermined voltage with a voltage applied from the power supply and outputs a voltage corresponding to a change in a voltage of the charge accumulation unit from the second terminal, based on a condition that an element voltage is a ground voltage. The common transistor outputs a voltage corresponding to a change in a voltage of the charge accumulation unit from the first terminal, based on the element voltage is higher than the ground voltage. The image processing unit generates a luminance image according to a change in the voltage output from the second terminal of the common transistor.

Abstract: The present invention provides a method for treating SWI/SNF complex-deficient cancers comprising a glutathione (GSH) metabolic pathway inhibitor, a pharmaceutical composition comprising a glutathione (GSH) metabolic pathway inhibitor for therapy in SWI/SNF complex-deficient cancers, and a glutathione (GSH) metabolic pathway inhibitor for use in treating SWI/SNF complex-deficient cancers. The present invention also provides a method for detecting and/or selecting a susceptible patient to a glutathione (GSH) metabolic pathway inhibitor.

Abstract: A camera module is configured to capture an optical image of a target area and includes a lens member, an imager, a light transmitting member, and a seat. The lens member is configured to receive light from the target area. The imager has a curved portion convex in a direction away from the lens member and is configured to capture the optical image formed on the curved portion. The light transmitting member optically couples the lens member and the imager. The seat has a supporting portion that supports an outer rim of the imager and a fluid space defined inside the supporting portion. A heat dissipation fluid undergoes convection in the fluid space. The curved portion is interposed between the light transmitting member and the seat having the supporting portion and the fluid space.

Abstract: The purpose is to reveal a polynucleotide that is a novel causal gene of pancreatic cancer and thereby provide a method for detecting the polynucleotide or a polypeptide encoded thereby to select a subject positive for the polynucleotide or polypeptide and a method expected to be useful for to identify patients suitable for therapies and a primer set therefor and a kit for detection. In the method, a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP6 gene or a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP26 gene, or a fusion protein encoded thereby is detected. The primer set comprises a sense primer designed for a part encoding CLDN18 and an antisense primer designed for a part encoding ARHGAP6 or a part encoding ARHGAP26.

Abstract: The purpose is to reveal a polynucleotide that is a novel causal gene of pancreatic cancer and thereby provide a method for detecting the polynucleotide or a polypeptide encoded thereby to select a subject positive for the polynucleotide or polypeptide and a method expected to be useful for to identify patients suitable for therapies and a primer set therefor and a kit for detection. In the method, a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP6 gene or a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP26 gene, or a fusion protein encoded thereby is detected. The primer set comprises a sense primer designed for a part encoding CLDN18 and an antisense primer designed for a part encoding ARHGAP6 or a part encoding ARHGAP26.

Abstract: A method for evaluating an efficacy of a chemoradiotherapy against squamous cell carcinoma comprises the following steps (a) to (c): (a) detecting an expression level of at least one gene selected from a SIM2 gene and genes co-expressed with the SIM2 gene in a squamous cell carcinoma specimen isolated from a subject; (b) comparing the expression level detected in the step (a) with a reference expression level of the corresponding gene; and (c) determining that an efficacy of a chemoradiotherapy against squamous cell carcinoma in the subject is high if the expression level in the subject is higher than the reference expression level as a result of the comparison in the step (b).

Abstract: A semiconductor storage device includes a semiconductor substrate and a plurality of first wiring layers stacked above the semiconductor substrate in a first direction orthogonal to the semiconductor substrate, and extending in a second direction intersecting the first direction and parallel to the semiconductor substrate. The device further includes a first memory pillar including a semiconductor layer and a first insulation layer extending in the first direction, the first insulation layer provided between the plurality of first wiring layers and the semiconductor layer so as to contact the semiconductor layer, and charge storage layers provided respectively between the plurality of first wiring layers and the first insulation layer. One or more of the charge storage layers is in contact with the first insulation layer. A plurality of second insulation layers is provided between each of the plurality of first wiring layers and each of the charge storage layers.

Abstract: The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an OCLN gene and a part of an ARHGAP26 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding OCLN and an antisense primer designed from a section encoding ARHGAP26.

Abstract: A storage device includes: a plurality of electrode films stacked in a first direction, and extending in a second direction intersecting the first direction; a first semiconductor film provided adjacent to the plurality of electrode films, and extending in the first direction; a first charge holding film provided between one electrode film among the plurality of electrode films, and the semiconductor film, and including any one of a metal, a metal compound, and a high dielectric material; and a second semiconductor film located between the first semiconductor film and the charge holding film, and extending in the first direction along the first semiconductor film. The second semiconductor film is electrically insulated from the plurality of electrode films, the first charge holding film, and the first semiconductor film.

Abstract: The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an RP2 gene and a part of an ARHGAP6 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding RP2 and an antisense primer designed from a section encoding ARHGAP6.

Abstract: The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an RP2 gene and a part of an ARHGAP6 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding RP2 and an antisense primer designed from a section encoding ARHGAP6.

Abstract: The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an OCLN gene and a part of an ARHGAP26 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding OCLN and an antisense primer designed from a section encoding ARHGAP26.